Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belimumab in Interstitial Lung Disease Associated With Connective Tissue Disease
NCT06572384Phase 3Recruiting
- Sponsor
- GSK
- Start
- Sep 2024
- Primary completion
- Aug 2029
- Modality
- Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of belimumab in interstitial lung disease (ILD), sponsored by GSK. Started Sep 2024; status: recruiting.
02
Drugs
belimumab
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT06572384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06572384.